Steady Rise in Insomnia Market: Valued at US$ 6.4 Billion by 2031 with 6.0% CAGR | TMR Insights

The global insomnia market, valued at US$3.8 billion in 2022, is poised for significant growth over the next decade. It is estimated to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2031, reaching US$6.4 billion by the end of 2031. This robust expansion reflects the increasing prevalence of sleep disorders, driven by modern lifestyle stressors, aging populations, and advancements in therapeutic options. As insomnia gains recognition as a public health concern, the market is set to nearly double in value, bolstered by contributions from major pharmaceutical players like Pfizer Inc., Merck & Co., Inc., and Takeda Pharmaceutical Company Limited, reinforcing its critical role in sleep health through 2031.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20246

Understanding the Insomnia Market

Insomnia, characterized by difficulty falling or staying asleep, affects millions globally, ranging from acute to chronic forms. The market encompasses pharmacological treatments-such as benzodiazepines, non-benzodiazepines (e.g., zolpidem), and orexin receptor antagonists (e.g., suvorexant)-alongside over-the-counter (OTC) remedies and cognitive behavioral therapy devices. The 2022 valuation of US$3.8 billion highlights its established importance, with the projected rise to US$6.4 billion by 2031 emphasizing its response to a growing sleep crisis.

The 6.0% CAGR signals a dynamic growth phase, balancing traditional therapies with innovative solutions. Insomnia's impact on mental and physical health drives sustained demand, ensuring market momentum.

Key Drivers of Market Growth

Several factors are propelling the insomnia market toward its US$6.4 billion milestone by 2031. First, the rising prevalence of insomnia is a primary driver. The American Sleep Association estimates that 10-30% of adults experience chronic insomnia, fueled by stress, anxiety, and screen time. Aging populations, more prone to sleep disturbances, further boost demand, aligning with the market's 6.0% CAGR as awareness of sleep health grows.

Second, advancements in pharmacotherapy are accelerating growth. Companies like Merck & Co., Inc., with its orexin antagonist Belsomra (suvorexant), and Vanda Pharmaceuticals Inc., known for Hetlioz (tasimelteon), are pioneering targeted treatments with fewer side effects than older hypnotics. Pfizer Inc.'s legacy in anxiolytics and Sanofi S.A.'s research into sleep aids enhance the therapeutic arsenal, driving the market toward US$6.4 billion as efficacy improves.

Third, lifestyle changes and healthcare focus are boosting the market. Sedentary habits, shift work, and digital overstimulation exacerbate insomnia, while rising mental health awareness prompts treatment-seeking behavior. Investments from firms like Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Limited in generics and novel formulations support accessibility, reinforcing the market's trajectory through 2031.

Leading Players:

Paratek Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Sanofi S.A
Merck & Co., Inc.
Viatris Inc.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20246

Market Segmentation and Regional Insights

The market segments by treatment type, distribution channel, and geography. Prescription drugs lead, with non-benzodiazepines and orexin antagonists dominating, followed by OTC sleep aids like diphenhydramine. Devices for cognitive behavioral therapy for insomnia (CBT-I) are an emerging niche. Distribution occurs via retail pharmacies, online platforms, and hospital pharmacies, with online sales surging due to convenience.

Regionally, North America held a significant share of the US$3.8 billion valuation in 2022, driven by high insomnia rates, advanced healthcare, and key players like Merck & Co., Inc. and Pfizer Inc. in the United States. Europe followed, with strong markets in Germany and the UK, supported by aging demographics. The Asia-Pacific region, however, is expected to see the fastest growth through 2031, fueled by urbanization, stress-related insomnia, and contributions from Sumitomo Dainippon Pharma Co., Ltd. and Takeda in Japan.

Challenges and Opportunities

The market faces challenges. Side effects of sleep medications-like dependency risks with benzodiazepines-limit long-term use, while regulatory scrutiny from agencies like the FDA delays approvals. Generic competition, led by firms like Viatris Inc. and Teva, pressures pricing, and stigma around sleep disorders in some regions slows adoption. The 6.0% CAGR reflects a market navigating these hurdles with steady progress.

These challenges, however, present opportunities. Companies like Sanofi S.A. and Paratek Pharmaceuticals, Inc., with expertise in novel compounds, could develop safer alternatives, supporting the push to US$6.4 billion. Digital therapeutics and wearables for sleep tracking offer growth potential, while expanding affordable options in emerging markets could exceed projections. Collaborations among these firms could accelerate innovation.

The Road to 2031

By 2031, the global insomnia market is expected to reach US$6.4 billion, reflecting nine years of strong growth at a 6.0% CAGR from US$3.8 billion in 2022. This milestone is driven by prevalence, therapeutic advancements, and contributions from industry leaders. As the forecast concludes, the market's trajectory suggests continued expansion, with potential for personalized sleep solutions to shape future growth.

In conclusion, the insomnia market demonstrates significant growth from 2023 to 2031. Rising from US$3.8 billion to US$6.4 billion, it addresses a pressing health challenge with impactful solutions. Stakeholders-including Pfizer, Merck, and Takeda-play a vital role in this success, ensuring effective, accessible treatments improve sleep worldwide through 2031 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Healthcare Biometrics Market: https://www.pharmiweb.com/press-release/2025-03-12/healthcare-biometrics-market-to-surpass-us-7408-billion-by-2035-driven-by-advancements-in-security-digital-health-solutions-tmr-insights

Healthcare Contract Research Outsourcing Market: https://www.pharmiweb.com/press-release/2025-03-12/healthcare-contract-research-outsourcing-market-to-surpass-us-6309-billion-by-2035-driven-by-increasing-demand-for-cost-effective-drug-development

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.